Table 4. Cox proportional hazard model for OS in KRAS mutant mCRC patients.

	Univariate analysis			Multivariate analysis
Variable	HR1	95%CI2	P	HR	95%CI	P
Age			0.59			0.67
≥65	1.16	0.75–1.66		1.11	0.7–1.74
<65	1.00			1.00
Sex			0.26			0.17
Female	1.25	0.85–1.83		1.33	0.89–1.98
Male	1.00			1.00
KRAS			0.98			1.0
Codon 13	0.99	0.62–1.60		1.00	0.6–1.66
Codon 12	1.00			1.00
Initial Dx as stage IV			0.067			0.07
Yes	1.43	0.98–2.10		3.91	0.92–16.63
No	1.00			1.00
Primary site			0.11			0.71
Distal	0.73	0.49–1.07		0.93	0.61–1.40
Proximal	1.00			1.00
Cetuximab			0.057			0.17
Never-used	0.68	0.45–1.01		0.73	0.46–1.15
Had been used	1.00			1.00
Oxaliplatin			0.028			0.001
Never-used	1.73	1.06–2.82		2.45	1.44–4.15
Had been used	1.00			1.00
Irinotecan			0.71			0.83
Never-used	0.91	0.55–1.51		1.07	0.58–1.96
Had been used	1.00			1.00
Bevacizumab			0.34			0.16
Never-used	0.83	0.56–1.22		0.73	0.48–1.13
Had been used	1.00			1.00
Chemotherapy in stage III			0.18			0.22
No	1.30	0.89–1.92		0.4	0.95–1.72
Yes	1.00			1.00
No. of mets			0.005			0.003
1	0.56	0.38–0.84		0.54	0.36–0.81
≥2	1.00			1.00

¹HR: hazard ratio. ²CI: confidence interval.